Joseph Salvino, Ph.D.

Joseph Salvino, Ph.D.


The Salvino Laboratory



Professor, Molecular & Cellular Oncogenesis Program, The Wistar Institute Cancer Center

Scientific Director, Molecular Screening & Protein Expression Facility

About the Scientist

Salvino is the first medicinal chemist to join Wistar’s staff, and his work to identify novel small molecule lead compounds provides a strong basis for collaboration with all Wistar researchers.

Salvino has more than 20 years of experience in drug discovery, including early stage hit-to-lead, lead optimization, and preclinical development where several candidates have successfully completed human clinical trials, including Entereg®, ADL-101, and Radezolid®. Prior to joining Wistar, Salvino was a professor in the Department of Pharmacology and Physiology at Drexel University College of Medicine. Prior to that, he held high level positions including vice president, senior director, and director in the biotechnology and pharmaceutical industries of Sterling Winthrop, Rhone-Poulenc Rorer, Aventis, Rib-X Pharmaceuticals, Adolor Corporation, and Cephalon.

Salvino received his Ph.D. in Organic Chemistry from Brown University and completed postdoctoral training in synthetic and medicinal chemistry at the University of Pennsylvania under the mentorship of K.C. Nicolaou and Ralph F. Hirschmann.

View Publications

The Salvino Laboratory

Salvino’s research is directed at drug discovery and development. His laboratory focuses on early drug discovery and small molecule tool compounds for in vivo target validation to confirm the pharmacological relevance and “drugability” of a therapeutic target. Medicinal chemistry optimization is focused on the design and creation of new chemical analogs to understand structured activity relationships critical for optimizing an early stage compound series. This effort is important to help identify a potential preclinical drug candidate or future therapeutic agent against a new biological target.


Postdoctoral Fellows

Farheen Mohammed, Ph.D.
Adi Poli, Ph.D.
You-Cai Xiao, Ph.D.
Valli Yellamelli, Ph.D.

Selected Publications

Kortagere, S., Mortensen , O.V., Xia, J., Lester, W., Fang, Y., Srikanth, Y., Salvino, J.M., Fontana, A.C.K. "Identification of Novel Allosteric Modulators of Glutamate Transporter EAAT2." ACS Chem Neurosci. 2018 Mar 21;9(3):522-534. doi: 10.1021/acschemneuro.7b00308. Epub 2017 Nov 30.

Tikhmyanova, N., Tutton, S., Martin, K.A., Lu, F., Kossenkov, A.V., Paparoidamis, N., Kenney, S., Salvino, J.M., Lieberman, P.M. "Small molecule perturbation of the CAND1-Cullin1-ubiquitin cycle stabilizes p53 and triggers Epstein-Barr virus reactivation." PLoS Pathog. 2017 Jul 17;13(7):e1006517. doi: 10.1371/journal.ppat.1006517. eCollection 2017 Jul.

Salvino, J.M., Srikanth, Y.V.V., Lou, R., Oyer, H.M., Chen, N., Kim, F.J., et al. "Novel small molecule guanidine Sigma1 inhibitors for advanced prostate cancer." Bioorg Med Chem Lett. 2017 May 15;27(10):2216-2220. doi: 10.1016/j.bmcl.2017.03.030. Epub 2017 Mar 18.

Thomas, J.D., Longen, C.G., Oyer, H.M., Chen, N., Maher, C.M., Salvino, J.M., Kania, B., Anderson, K.N., Ostrander, W.F., Knudsen, K.E., et al. "Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer." Cancer Res. 2017 May 1;77(9):2439-2452. doi: 10.1158/0008-5472.CAN-16-1055. Epub 2017 Feb 24.

Shen, F., Zhang, Y., Jernigan, D.L., Feng, X., Yan, J., Garcia, F.U., Meucci, O., Salvino, J.M., Fatatis, A. "Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells." Mol Cancer Res. 2016 Jun;14(6):518-27. doi: 10.1158/1541-7786.MCR-16-0013. Epub 2016 Mar 21.

View Additional Publications